Back to Search
PRIYANKA SISTA, M.D.
M.D.
Emergency Medicine Physician
NPI: 1427412576Individual
Specialties, Licenses & Credentials
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
125.068386(IL)2022-01834(NC)
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (16)
Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples.
PMID 19474648·AIDS·2009
8-other
Nine-year trends in clinically relevant reduced susceptibility of HIV-1 to antiretrovirals.
PMID 19168389·J Clin Virol·2009
8-other
A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.
PMID 19114860·AIDS·2009
4-observational
The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.
PMID 18472298·J Clin Virol·2008
8-other
Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.
PMID 16706613·AIDS Res Hum Retroviruses·2006
3-trial
Beta-hairpins with native-like and non-native hydrogen bonding patterns could form during the refolding of staphylococcal nuclease.
PMID 16386445·J Mol Graph Model·2006
8-other
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
PMID 16160172·J Virol·2005
8-other
Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy.
PMID 15626952·Pediatr Infect Dis J·2004
3-trial
Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.
PMID 15316339·AIDS·2004
3-trial
Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children.
PMID 15295220·Pediatr Infect Dis J·2004
3-trial
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).
PMID 15078945·J Virol·2004
8-other
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
PMID 14518696·Antivir Ther·2003
3-trial
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.
PMID 12646792·AIDS·2003
3-trial
Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children.
PMID 12237598·Pediatr Infect Dis J·2002
3-trial
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
PMID 12167274·AIDS Res Hum Retroviruses·2002
3-trial
Heptad-repeat regions of respiratory syncytial virus F1 protein form a six-membered coiled-coil complex.
PMID 10995236·Biochemistry·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 211 E ONTARIO ST, SUITE 200
CHICAGO, IL 60611 - Phone
- (312) 926-9512
Quick Facts
- NPI
- 1427412576
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 3
- Publications
- 16
Are you this provider?
Claim Your Profile